These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14709250)

  • 1. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
    Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
    Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
    Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
    Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
    J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
    Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
    J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis.
    Blanco J; Barretina J; Henson G; Bridger G; De Clercq E; Clotet B; Esté JA
    Antimicrob Agents Chemother; 2000 Jan; 44(1):51-6. PubMed ID: 10602722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
    Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
    AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
    Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
    J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
    Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
    J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
    Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
    J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
    Armand-Ugón M; Quiñones-Mateu ME; Gutiérez A; Barretina J; Blanco J; Schols D; De Clercq E; Clotet B; Esté JA
    Antivir Ther; 2003 Feb; 8(1):1-8. PubMed ID: 12713058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
    Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
    J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
    De Clercq E
    Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4(+) T cells.
    Zhang Y; Hatse S; De Clercq E; Schols D
    J Virol; 2000 Feb; 74(4):2011-6. PubMed ID: 10644374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
    Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
    Donzella GA; Schols D; Lin SW; Esté JA; Nagashima KA; Maddon PJ; Allaway GP; Sakmar TP; Henson G; De Clercq E; Moore JP
    Nat Med; 1998 Jan; 4(1):72-7. PubMed ID: 9427609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry.
    Hatse S; Princen K; Vermeire K; Gerlach LO; Rosenkilde MM; Schwartz TW; Bridger G; De Clercq E; Schols D
    FEBS Lett; 2003 Jul; 546(2-3):300-6. PubMed ID: 12832058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.
    Labrosse B; Brelot A; Heveker N; Sol N; Schols D; De Clercq E; Alizon M
    J Virol; 1998 Aug; 72(8):6381-8. PubMed ID: 9658078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells.
    Schols D; De Clercq E
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2203-5. PubMed ID: 9747729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.